Scheer Partners Scientific Real Estate

In this episode of #BioBlast, Devin Zitelman caught up with Robert Storey, a seasoned executive and trailblazer in accelerating Maryland's #MedTech sector, at The LaunchPort - a medical device venture center in the Baltimore Peninsula where he is the Founder + Managing Partner. He is the Managing Director of The MVR Company, which focuses on the assessment and creation of new ventures, and is Chairman and board member for a number of early stage MedTech companies. Bob is appointed as the Vice Chairman of the State's Maryland Department of Commerce's Life Science Advisory Board, serves on the Investment Advisory Board of Wexford Science & Technology, LLC, and was most recently named the Director of the Evaluation Core for the NeuroTech Harbor (NTH) with The Johns Hopkins University & Howard University. They cover a wide range of important topics, including startup formation, the innovation economy, and transformative trends in the sector. This is a must watch! Click the link below ▶▶▶ Vixiar Medical The National Institutes of Health The MVR Company Maryland MEP MD Anderson Cancer Center Greater Baltimore Committee South Duvall | Commercial Real Estate Investments University of Maryland, Baltimore (UMB) University of Maryland Johns Hopkins Technology Ventures (JHTV) University of Maryland BioPark Maryland Tech Council BioHealth Innovation, Inc. BioBuzz

The next episode of #BioBlast with Devin Zitelman, MBA is live on YouTube and streaming on #podcast streaming platforms! We are excited to feature Dr. Samir Khleif, Founder & CEO, Georgiamune Inc., and Director, Center for Advanced Immunotherapy #Research & Professor of Oncology at Georgetown University. Dr. Khleif is the former Director of the Georgia Cancer Center, and his distinguished career includes time as the Director General & CEO of the King Hussein Institute for Biotechnology and Cancer in Amman, Jordan, and as Chief, Cancer Vaccine Section, at the National Cancer Institute (NCI). At Georgiamune, his team is developing a target discovery platform to fight #cancer and autoimmune diseases, including a portfolio of first-in-class assets, across different phases of clinical trials, with the potential to target large indications. They have raised over $75M from #investors and continue to push the boundaries of #scientific #discovery. To put it simply, there is a lot we can glean from his experience and this is one interview you don't want to miss! Tune in by clicking on the link below 👇👇

🎉 🎉 Celebrating Episode 2️⃣ 0️⃣ of #BioBlast!! Devin Zitelman is joined by leaders and executives in life #science and biotech to discuss their career journey to the C-suite, market trends, #business strategies, tech commercialization, #capital raising, and more. The latest episode ft. Jeff Galvin, CEO, American Gene Technologies® International Inc. and Addimmune™, companies developing next generation cell and gene therapies for infectious diseases, cancers, and inherited disorders. Their proprietary delivery platform has enabled the company to raise significant #venture investment while transforming #patient care. ✈ His career journey from a #software engineer in Silicon Valley and early-retirement to commercializing a portfolio of patented technologies. Plus, how those early experiences impact his decision making and developing culture. 👨🔬 Approaching clinicals, including Phase I safety and efficacy, in alignment with patient's condition for cell and gene therapies while obtaining investments for future trials. 💻 Future implications for #AI and #ML technologies on molecular model development and where we are in the adoption as an industry relative to some of the LLMs that are currently available. Tune in by clicking the link below ⬇ and be sure to subscribe! Now streaming wherever you get your #podcast.

✨ Delighted to share the 19th episode of #BioBlast with Devin Zitelman ft. Chandra Briggman, President & CEO, Activation Capital! ✨ 👩🔬 Chandra went from directing Venture Café Cambridge, the global network's flagship location, to leading innovation ecosystem development in City of Richmond, Virginia focused on #STEM and #biotech. She discusses her strategy for steering investments into the city's #health + #lifescience sector. 🏗 Planning a $53 million innovation center in downtown Richmond in the VA Bio+Tech Park in collaboration with VIPC | Virginia Innovation Partnership Corporation + Virginia Commonwealth University (that includes 35K SF of lab and creative office plus another 45K SF dedicated to an incubator with shared labs, private offices, and community gathering spaces). 💊 Leading economic development initiatives and creating "mission focused" conditions for a newly invigorated $100M cluster accelerator for advanced #pharmaceutical #manufacturing and research. 💡 Increasing commercialization and assisting founders with an intentional approach to capacity-building for the greater #Virginia "triangle." 💪 Approaches to executive leadership, strategic planning, and attracting outside funding by "turning over every stone" to achieve flywheel investments across funding categories. Commonwealth of Virginia Massachusetts Institute of Technology #alumni Hon. Glenn Youngkin National Science Foundation (NSF) National Institute of Mental Health (NIMH) Levar Stoney Startup Virginia Venture X Richmond Virginia Chamber of Commerce Scheer Partners South Duvall | Commercial Real Estate Investments Economic Innovation Group

After productive time off including a trip to the Biotechnology Innovation Organization Conference in San Diego we're back with the next episode of #BioBlast!👏 👏 👏 Devin Zitelman connects with Carsten Brunn, President & CEO, Cartesian Therapeutics (NASDAQ: RNAC), a publicly traded, clinical-stage #biotech company pioneering #mRNA cell therapy for autoimmune diseases. The two discuss the company's $110M reverse-merger with Selecta Biosciences, plus: 🔎 Professional story and career "arcs" that inform his leadership style and management approach. ☕ The integration of founder (Murat Kalayoglu + Michael Singer) and executive teams, approach to culture-building and talent acquisition. 💉 Managing a pipeline of novel assets across multiple indications and phases of clinical trials. 🔭 Differences and advantages of hosting operations in #Boston and #Maryland including their biomanufacturing + GMP facilities. 💰 Trends in venture and development capital. ...and more! 📹 Tune in and subscribe to #BioBlast, now streaming on YouTube & Spotify for Podcasters plus anywhere you access your #podcasts. MassBio Maryland Tech Council Maryland Department of Commerce BioBuzz Nasdaq Frederick Innovative Technology Center, Inc Argot Partners Scheer Partners Velogic The National Institutes of Health Disclaimer: The views expressed in this promotion are based on personal opinions and should not be considered investment advice. Scheer Partners employs individuals that own shares in Cartesian Therapeutics stock.

ATCC’s own Ruth R Cheng, GM & SVP, Research and Industrial Solutions, sat down with Devin Zitelman for an episode of #BioBlast to discuss ATCC’s impact on the global scientific community, trends in the life sciences industry, the impacts of emerging technologies, Ruth’s approach to leadership, and more! Watch the full interview here: https://ow.ly/Mp7h50S4nFM

Look out for our Director, Scientific Real Estate Advisory Services, Devin Zitelman at next week's Biotechnology Innovation Organization (#BIO) Conference in San Diego. You can also find him on the one-on-one partnering platform or send a direct message to schedule time to connect!

📫📫 This episode of #BioBlast with Devin Zitelman ft. Kelly Schulz, Chief Executive Officer, Maryland Tech Council!! Kelly leads MTC, and 730+ members, on a shared mission to propel #Maryland as the # 1️⃣ innovation economy for life sciences and technology in the country. MTC is a designated affiliate for the Biotechnology Innovation Organization and the largest #technology and #scientific trade association in the state. She is accustomed to leadership roles given her time as the Secretary of the Maryland Department of Commerce and Maryland Department of Labor. Kelly is a mother, wife, successful small business owner, and served on the MD House of Delegates (representing Frederick County) - which adds to her tool box for developing original strategies to expand the state's #bioeconomy. We discuss her approach to #STEM advocacy, convergence of #biotech with emerging #tech, scaling an entrepreneurial ecosystem, the importance of community building, and "pulled back the curtain" on launching BioHub Maryland. Tune in for the full video today and be sure to subscribe to #BioBlast! 🚧 Disclaimer: Scheer Partners is an active member of MTC and serves on their Board of Directors.

#ICYMI! ATCC is a global #nonprofit biological resource center and standards organization that has one of the largest libraries of authenticated (human and animal) #cell lines, microbial strains, and other cell products in their biorepositories. Their services include authentication, production, and federal solutions such as #clinical study support. Ruth R Cheng, PhD, GM & SVP, Research and Industrial Solutions, joined the team in 2020 with a background in healthcare and life science innovation. She brings an interdisciplinary knowledge of major #therapeutic areas, product development, strategic planning, and #corporate venturing and M&A. She joins Devin Zitelman on #BioBlast to discuss her role as a life science #executive and interactions with public and private partners. ✳ Risk mitigation strategies 🚚 Supply chain management ☕ Managing high-performance teams 🔬 Trends in the cell banking industry 🤖 Impact of AI and ML on scientific research View the full interview by clicking the link: 👉👉👉 https://lnkd.in/gdK_3cdB BioBuzz National Institute of Standards and Technology (NIST) University of Michigan Cornell University Centers for Disease Control and Prevention National Institute of Allergy and Infectious Diseases (NIAID) #cell #banking #science #discovery #lab #realestate #future

Deka Biosciences, Inc is radically changing #immunotherapy by developing a robust pipeline of cytokine technologies for personalized treatments of cancer and inflammatory diseases. Their Founder & CEO, John Mumm, met with Devin Zitelman on the this episode of #BioBlast. With the rise of precision #medicine resulting from discoveries in mRNA and cell and gene therapies, #disease targeting platforms provide a pathway to the next-generation of therapies based on each patient's individual immune responses. John has over 20 years of experience in academic and biotechnology + pharmaceutical industries including stints at Merck, ARMO BioSciences (scientific co-founder), and MedImmune (acquired by AstraZeneca). His research at Stanford University and the UT MD ANDERSON CANCER CENTER has primarily focused on the interface between cancer biology and adaptive immune response. We discuss his journey to #Maryland, company formation, taking a familial approach to leadership + team building, and important trends for the future of oncology and immunology #innovation. His story is fascinating and we can learn a lot from John! Check out the full video in the link below ⬇ P.S. Scheer Partners is delighted to welcome Nick Mumm to our team as a summer intern!